440 related articles for article (PubMed ID: 24690241)
41. Experimental challenges to targeting poorly characterized GPCRs: uncovering the therapeutic potential for free fatty acid receptors.
Hudson BD; Smith NJ; Milligan G
Adv Pharmacol; 2011; 62():175-218. PubMed ID: 21907910
[TBL] [Abstract][Full Text] [Related]
42. Emerging opportunities for allosteric modulation of G-protein coupled receptors.
Wang CI; Lewis RJ
Biochem Pharmacol; 2013 Jan; 85(2):153-62. PubMed ID: 22975406
[TBL] [Abstract][Full Text] [Related]
43. Synthetic nanobodies as angiotensin receptor blockers.
McMahon C; Staus DP; Wingler LM; Wang J; Skiba MA; Elgeti M; Hubbell WL; Rockman HA; Kruse AC; Lefkowitz RJ
Proc Natl Acad Sci U S A; 2020 Aug; 117(33):20284-20291. PubMed ID: 32753386
[TBL] [Abstract][Full Text] [Related]
44. New advances in production and functional folding of G-protein-coupled receptors.
Banères JL; Popot JL; Mouillac B
Trends Biotechnol; 2011 Jul; 29(7):314-22. PubMed ID: 21497924
[TBL] [Abstract][Full Text] [Related]
45. Engineering therapeutic antibodies targeting G-protein-coupled receptors.
Jo M; Jung ST
Exp Mol Med; 2016 Feb; 48(2):e207. PubMed ID: 26846450
[TBL] [Abstract][Full Text] [Related]
46. A guide to: generation and design of nanobodies.
Muyldermans S
FEBS J; 2021 Apr; 288(7):2084-2102. PubMed ID: 32780549
[TBL] [Abstract][Full Text] [Related]
47. Nanobodies as probes to investigate purinergic signaling.
Eggers M; Rühl F; Haag F; Koch-Nolte F
Biochem Pharmacol; 2021 May; 187():114394. PubMed ID: 33388283
[TBL] [Abstract][Full Text] [Related]
48. Antigen Design for Successful Isolation of Highly Challenging Therapeutic Anti-GPCR Antibodies.
Ju MS; Jung ST
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153215
[TBL] [Abstract][Full Text] [Related]
49. Single-Domain Antibodies or Nanobodies: A Class of Next-Generation Antibodies.
Khodabakhsh F; Behdani M; Rami A; Kazemi-Lomedasht F
Int Rev Immunol; 2018; 37(6):316-322. PubMed ID: 30741045
[TBL] [Abstract][Full Text] [Related]
50. Nanobodies in cancer.
Verhaar ER; Woodham AW; Ploegh HL
Semin Immunol; 2021 Feb; 52():101425. PubMed ID: 33272897
[TBL] [Abstract][Full Text] [Related]
51. DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility.
Urban DJ; Roth BL
Annu Rev Pharmacol Toxicol; 2015; 55():399-417. PubMed ID: 25292433
[TBL] [Abstract][Full Text] [Related]
52. Nanobodies derived from Camelids represent versatile biomolecules for biomedical applications.
Yu X; Xu Q; Wu Y; Jiang H; Wei W; Zulipikaer A; Guo Y; Jirimutu ; Chen J
Biomater Sci; 2020 Jul; 8(13):3559-3573. PubMed ID: 32490444
[TBL] [Abstract][Full Text] [Related]
53. Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology.
DeWire SM; Violin JD
Circ Res; 2011 Jul; 109(2):205-16. PubMed ID: 21737816
[TBL] [Abstract][Full Text] [Related]
54. New insights into GPCR function: implications for HTS.
Eglen RM; Reisine T
Methods Mol Biol; 2009; 552():1-13. PubMed ID: 19513638
[TBL] [Abstract][Full Text] [Related]
55. Single-domain antibodies: a versatile and rich source of binders for breast cancer diagnostic approaches.
Even-Desrumeaux K; Fourquet P; Secq V; Baty D; Chames P
Mol Biosyst; 2012 Sep; 8(9):2385-94. PubMed ID: 22772166
[TBL] [Abstract][Full Text] [Related]
56. Dimers and beyond: The functional puzzles of class C GPCRs.
Kniazeff J; Prézeau L; Rondard P; Pin JP; Goudet C
Pharmacol Ther; 2011 Apr; 130(1):9-25. PubMed ID: 21256155
[TBL] [Abstract][Full Text] [Related]
57. Applications of nanobodies in plant science and biotechnology.
Wang W; Yuan J; Jiang C
Plant Mol Biol; 2021 Jan; 105(1-2):43-53. PubMed ID: 33037986
[TBL] [Abstract][Full Text] [Related]
58. Speed up to find the right ones: rapid discovery of functional nanobodies.
Rothbauer U
Nat Struct Mol Biol; 2018 Mar; 25(3):199-201. PubMed ID: 29507400
[No Abstract] [Full Text] [Related]
59. New tools for G-protein coupled receptor (GPCR) drug discovery: combination of baculoviral expression system and solid state NMR.
Ratnala VR
Biotechnol Lett; 2006 Jun; 28(11):767-78. PubMed ID: 16786240
[TBL] [Abstract][Full Text] [Related]
60. Molecular modeling of vasopressin receptor and in silico screening of V1b receptor antagonists.
Hagiwara Y; Ohno K; Kamohara M; Takasaki J; Watanabe T; Fukunishi Y; Nakamura H; Orita M
Expert Opin Drug Discov; 2013 Aug; 8(8):951-64. PubMed ID: 23682717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
